4//SEC Filing
Van Strydonck, Gerald E. 4
Accession 0001209191-19-052506
CIK 0001205922other
Filed
Oct 3, 8:00 PM ET
Accepted
Oct 4, 10:57 AM ET
Size
12.0 KB
Accession
0001209191-19-052506
Insider Transaction Report
Form 4
VACCINEX, INC.VCNX
Van Strydonck, Gerald E.
Director
Transactions
- Award
Stock Option (Right to Buy)
2019-09-30+1,856→ 1,856 totalExercise: $7.17From: 2019-09-30Exp: 2019-09-27→ Common Stock (1,856 underlying)
Holdings
- 4,500
Stock Option (Right to Buy)
Exercise: $10.00Exp: 2020-03-06→ Common Stock (4,500 underlying) - 7,500
Stock Option (Right to Buy)
Exercise: $14.90Exp: 2023-03-06→ Common Stock (7,500 underlying) - 2,501
Stock Option (Right to Buy)
Exercise: $5.26Exp: 2029-03-30→ Common Stock (2,501 underlying) - 6,396
Stock Option (Right to Buy)
Exercise: $13.60Exp: 2027-09-15→ Common Stock (6,396 underlying) - 7,718
Stock Option (Right to Buy)
Exercise: $7.78From: 2020-05-15→ Common Stock (7,718 underlying)
Footnotes (3)
- [F1]Exercisable in full as of the date of this report.
- [F2]Except as otherwise provided in the award notice, this option expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first.
- [F3]Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the third quarter of 2019. The number of options was calculated in accordance with the Black-Scholes valuation model and all of such options are immediately exercisable.
Documents
Issuer
VACCINEX, INC.
CIK 0001205922
Entity typeother
Related Parties
1- filerCIK 0001748247
Filing Metadata
- Form type
- 4
- Filed
- Oct 3, 8:00 PM ET
- Accepted
- Oct 4, 10:57 AM ET
- Size
- 12.0 KB